Fig. 4

Cell viability of 4T1 cells treated with Gemcitabine (Gem) (12.5, 25, 37.5 and 50 µg/mL), platinumCobalt@Gem-hyaluronic acid (HA)-poly[ethylene glycol] (PtCo@Gem-HA-PEG) with and without photodynamic therapy (PDT) (25, 50, 75 and 100 µg/mL) at 24 (A) and 48 (B) hours of incubation. C, D γ-H2AX foci immunofluorescence staining and number of foci per nucleous of 4T1 cells incubated in different treatments. The scale bar is 20 μm. E, F Representative DCF staining images of 4T1 cells and mean fluorescent intensity in different treatments for ROS evaluation. The scale bar is 60 μm. G Annexin V and PI staining assays of 4T1 cells treated in different treatments. Different letters a, b and c are significantly different at P < 0.05. ^*P < 0.05, ^**P < 0.01, and ^***P < 0.001 indicate significant differences